Comparative Pharmacology
Head-to-head clinical analysis: BETATREX versus LOCOID LIPOCREAM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BETATREX versus LOCOID LIPOCREAM.
BETATREX vs LOCOID LIPOCREAM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Betamethasone is a corticosteroid that binds to glucocorticoid receptors, modulating gene expression to reduce inflammation, suppress immune response, and alter connective tissue response.
Locoid Lipocream contains hydrocortisone butyrate, a synthetic corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive properties. It acts by inducing phospholipase A2 inhibitory proteins (lipocortins), thereby inhibiting the release of arachidonic acid and subsequent synthesis of prostaglandins and leukotrienes. It also suppresses cytokine production, reduces mast cell degranulation, and decreases vascular permeability.
Adults: 1 gram intravenously every 24 hours. For severe infections, 1 gram every 12 hours may be used.
Apply a thin layer to affected area twice daily. Maximum duration of continuous treatment: 4 weeks.
None Documented
None Documented
Terminal elimination half-life is 8-12 hours in adults with normal renal function, allowing twice-daily dosing.
Terminal elimination half-life: ~6-8 hours (hydrocortisone butyrate); clinical context: supports twice-daily dosing
Renal elimination of unchanged drug accounts for approximately 60-70% of the dose; biliary excretion contributes about 20-25%, with the remainder eliminated via feces.
Renal: ~1.5% as unchanged hydrocortisone butyrate and metabolites; Biliary/fecal: ~85% as metabolites
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid